Marie-Christine Bissery

This inventor holds 22 USPTO granted patents and 8 published patent applications, plus 3 CIPO patents and 4 EPO patents, primarily in Antitumor Compositions. Top assignees: Aventis Pharma S.a., Rhone-Poulenc Rorer S.a., Regeneron Pharmaceuticals, Inc.. Active years: 1998-2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Marie-Christine Bissery. Retrieved from https://idiyas.com/inventor/marie-christine-bissery

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 22 (Patent Applications = 8)

% Patents Active = 45.5

CIPO Patents = 3

EPO Patents = 4 (Patent Applications = 3)

Average Co-Inventor Count = 1.2

ph-index = 10

Forward Citations = 340(Granted Patents)

Location History:

Vitry Sur Seine, FR (1998 - 2012)
Charenton le Pont, FR (2013)

Company Filing History:

Rhone-Poulenc Rorer S.a.

patents

1 out of 1,484

Regeneron Pharmaceuticals, Inc.

patents

where one patent can have more than one assignee

Years Active: 1998-2013

Loading Chart...

Areas of Expertise:

VEGF-Inhibiting Agent

5FU

Taxane Derivatives

Epidophyllotoxins

Docetaxel

Doxorubicin

Camptothecin

Alkylating Agent

Combination Therapy

Cancer Treatment

Anticancer Agents

Nanoparticles

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8388963 - Antitumor combinations containing a VEGF-inhibiting agent and 5FU or a derivative thereof (2013-03-05),

2. 8124650 - Antitumor combinations containing taxane derivatives and epidophyllotoxins (2012-02-28),

3. 8101652 - Antitumour combinations containing taxotere and 5-fluorouracil (2012-01-24),

4. 7994212 - Method of treating cancer with docetaxel and doxorubicin (2011-08-09),

5. 7989489 - Method of treating leukemia with docetaxel and vinca alkaloids (2011-08-02),

6. 7851443 - Combination comprising combretastatin and anticancer agents (2010-12-14),

7. 6960596 - Composition comprising camptothecin or a comptothecin derivative and a platin derivative for the treatment of cancer (2005-11-01),

8. 6933320 - Combination comprising combretastatin and anticancer agents (2005-08-23),

9. 6664242 - Composition and method comprising CPT-11 and a pyrimidine derivative for the treatment of cancer (2003-12-16),

10. 6562834 - Combination comprising camptothecin and a stilbene derivative for the treatment of cancer (2003-05-13),

11. 6548488 - Composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer (2003-04-15),

12. 6545010 - Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer (2003-04-08),

13. 6503889 - Composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer (2003-01-07),

14. 6441026 - Antitumor compositions containing taxane derivatives (2002-08-27),

15. 6403634 - Use of taxoid derivatives (2002-06-11),

Title: Innovations and Contributions of Marie-Christine Bissery in Antitumor Treatments

Introduction

Marie-Christine Bissery, based in Vitry sur Seine, France, is a prominent inventor known for her significant contributions to the field of anti-cancer therapies. With an impressive portfolio of 22 patents, she has dedicated her career to the development of effective treatments for neoplastic diseases. Her work exemplifies the impact of innovation in pharmaceutical research and development.

Latest Patents

Among her noteworthy inventions, Bissery's most recent patents include:

1. **Antitumor combinations containing a VEGF-inhibiting agent and 5FU or a derivative thereof** - This invention focuses on therapeutic combinations that include a VEGF inhibitor paired with 5-fluorouracil or a 5-fluoropyrimidine derivative. These combinations have demonstrated therapeutic efficacy in treating neoplastic diseases, highlighting Bissery's commitment to advancing cancer treatment options.

2. **Antitumor combinations containing taxane derivatives and epidophyllotoxins** - This patent describes innovative combinations of taxanes and at least one epidophyllotoxin for the treatment of neoplastic diseases. Bissery's work in this area continues to push the boundaries of oncological pharmacology.

Career Highlights

Marie-Christine Bissery has made significant strides in her career by collaborating with renowned pharmaceutical companies. She has worked with major organizations such as Aventis Pharma S.A. and Rhône-Poulenc Rorer S.A., where she focused on research that bridges academic knowledge and practical applications in cancer therapy. Her career has been marked by a relentless pursuit of innovation in pharmaceuticals.

Collaborations

Throughout her professional journey, Bissery has collaborated with esteemed colleagues including Patricia Vrignaud and Marielle Chiron-Blondel. These partnerships have enriched her research endeavors and contributed to the successful development of her patented inventions.

Conclusion

Marie-Christine Bissery's dedication to innovation in the pharmaceutical industry has led to the creation of valuable antitumor treatments. Her extensive patent portfolio and collaborations with leading companies demonstrate her significant influence on cancer research. As she continues to drive advancements in cancer therapy, her work remains a beacon of inspiration for future inventors in the field.

Profile summary based on public USPTO records.